Patents by Inventor Christina Marie Dalby

Christina Marie Dalby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MIR-92 INHIBITORS AND USES THEREOF
    Publication number: 20190194662
    Abstract: The present invention provides oligonucleotide inhibitors of miR-92 and methods of using said inhibitors for inhibiting the function and/or activity of miR-92 in a subject in need thereof. The present invention also provides methods for evaluating or monitoring the efficacy of a therapeutic for promoting wound healing and selecting a subject for treatment with a therapeutic that modulates miR-92 function and/or activity.
    Type: Application
    Filed: March 13, 2019
    Publication date: June 27, 2019
    Inventors: Christina Marie Dalby, Corrie Lynn Gallant-Behm, Aimee Jackson, Kathryn Hutnick, Anita Seto
  • MiR-92 inhibitors and uses thereof
    Patent number: 10280422
    Abstract: The present invention provides oligonucleotide inhibitors of miR-92 and methods of using said inhibitors for inhibiting the function and/or activity of miR-92 in a subject in need thereof. The present invention also provides methods for evaluating or monitoring the efficacy of a therapeutic for promoting wound healing and selecting a subject for treatment with a therapeutic that modulates miR-92 function and/or activity.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: May 7, 2019
    Assignee: MIRAGEN THERAPEUTICS, INC.
    Inventors: Christina Marie Dalby, Corrie Lynn Gallant-Behm, Aimee Jackson, Kathryn Hutnick, Anita Seto
  • MIR-19 MODULATORS AND USES THEREOF
    Publication number: 20180250325
    Abstract: The present invention provides miR-19 modulators and uses thereof, such as for promoting angiogenesis and/or wound healing with miR-19 inhibitors alone or in combination with other agents. The present invention also provides methods of treating or preventing arterial and cardiac conditions with a miR-19 inhibitor. Also provided are oligonucleotides with chemical motifs that are miR-19 inhibitors, and methods of using the oligonucleotides for inhibiting the function or activity of miR-19 in a subject in need thereof.
    Type: Application
    Filed: September 22, 2016
    Publication date: September 6, 2018
    Inventors: William C. SESSA, Christina Marie DALBY, Corrie Lynn GALLANT-BEHM
  • MIR-92 INHIBITORS AND USES THEREOF
    Publication number: 20180237779
    Abstract: The present invention provides oligonucleotide inhibitors of miR-92 and methods of using said inhibitors for inhibiting the function and/or activity of miR-92 in a subject in need thereof. The present invention also provides methods for evaluating or monitoring the efficacy of a therapeutic for promoting wound healing and selecting a subject for treatment with a therapeutic that modulates miR-92 function and/or activity.
    Type: Application
    Filed: January 23, 2018
    Publication date: August 23, 2018
    Inventors: Christina Marie Dalby, Corrie Lynn Gallant-Behm, Aimee Jackson, Kathryn Hutnick, Anita Seto
  • miR-92 inhibitors and uses thereof
    Patent number: 9885042
    Abstract: The present invention provides oligonucleotide inhibitors of miR-92 and methods of using said inhibitors for inhibiting the function and/or activity of miR-92 in a subject in need thereof. The present invention also provides methods for evaluating or monitoring the efficacy of a therapeutic for promoting wound healing and selecting a subject for treatment with a therapeutic that modulates miR-92 function and/or activity.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: February 6, 2018
    Assignee: MIRAGEN THERAPEUTICS, INC.
    Inventors: Christina Marie Dalby, Corrie Lynn Gallant-Behm, Aimee Jackson, Kathryn Hutnick, Anita Seto
  • Oligonucleotide-based inhibitors comprising locked nucleic acid motif
    Patent number: 9803202
    Abstract: The present invention relates to chemical modification motifs for oligonucleotides. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or mRNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: October 31, 2017
    Assignee: MIRAGEN THERAPEUTICS, INC.
    Inventors: Eva van Rooij, Christina Marie Dalby, Rusty L. Montgomery
  • MIR-92 INHIBITORS AND USES THEREOF
    Publication number: 20160208258
    Abstract: The present invention provides oligonucleotide inhibitors of miR-92 and methods of using said inhibitors for inhibiting the function and/or activity of miR-92 in a subject in need thereof. The present invention also provides methods for evaluating or monitoring the efficacy of a therapeutic for promoting wound healing and selecting a subject for treatment with a therapeutic that modulates miR-92 function and/or activity.
    Type: Application
    Filed: January 20, 2016
    Publication date: July 21, 2016
    Inventors: Christina Marie Dalby, Corrie Lynn Gallant-Behm, Aimee Jackson, Kathryn Hutnick, Anita Seto